YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Telix Pharmaceuticals Limited First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (br…
Geopolitics, trade rules, and energy regulation are colliding to reshape how risk is priced, insured, and transferred. That mix creates potential openings for investors who understand which stocks are most exposed to these headlines, and w…
Telix Pharmaceuticals Limited (TLX) closed the last trading session at $11.34, gaining 4.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any gui…
FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. The designation recognizes the program's potential to address an important u…
Bond yields at two decade highs have reset borrowing costs across the globe, which puts pressure on heavily indebted businesses but shines a spotlight on Australian companies that can fund their own expansion. When insiders own meaningful…
Telix Pharmaceuticals has delivered a very strong 185.1% share price gain over the past five years, yet the latest acquisition plans and product approvals leave a clear question about whether that journey is still backed by its cash flows.…
Telix Pharmaceuticals (ASX:TLX) has moved to lead a merger with ITM Isotope Technologies Munich SE, a radioisotope producer and radiopharmaceutical developer, in a transaction valued at up to A$2.35b. Telix Pharmaceuticals shares trade at…
Telix Pharmaceuticals Limited (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE. The deal is worth up to $2.35 billion. Telix will pay $1.65 billion upfront, before cash and debt. A further $700 million foll…
Telix Pharmaceuticals (ASX: TLX) has agreed to acquire ITM Isotope Technologies Munich SE in a deal valued at US$2.35b. The transaction gives Telix control of a major global producer of medical radioisotopes used in cancer diagnosis and tr…
[Stock market trading growth graph] Stock futures rose Monday morning as trade optimism ahead of the U.S.-China summit and steady Middle East oil flows outweighed regional geopolitical tensions. Here are some of Monday's biggest stock move…
Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts. Continue Reading
Telix Pharmaceuticals (TLX) agreed to acquire Germany-based ITM Isotope Technologies Munich in a dea PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn. The deal combines Telix's operations with ITM's radioisotope production business and late-stage treatment…
[Two scientists in conversation, standing in laboratory] Solskin * Australian biotechnology company Telix Pharmaceuticals (TLX [https://seekingalpha.com/symbol/TLX]) has agreed to acquire Germany's ITM Isotope in a $1.65B deal, the compani…
Transformational merger reinforces Telix's long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commerci…
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
When news breaks that Google's Gemini can autonomously hack real companies, the story quickly shifts from science fiction to balance sheet risk. Cyber insurance and tech liability insurers suddenly move from background players to potential…
Company Logo The global theranostics market is set for significant growth through 2036, driven by precision medicine, rising cancer prevalence, molecular imaging advances and targeted radiopharmaceutical therapies. Oncology leads adoption,…
The race for pharmaceutical dominance often centers on chronic disease management. For investors, deciding between Novo Nordisk (NYSE:NVO) and Regeneron Pharmaceuticals (NASDAQ:REGN) requires a close look at their unique market strengths.…
Telix Pharmaceuticals Limited Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatme…
[Magnetic resonance imaging (MRI) or CT scan of the brain, sinusitis, sinonasal mass, brain tumours. Metastasis.] Md Babul Hosen/iStock via Getty Images The Food and Drug Administration approved Telix Pharmaceuticals’ (TLX [https://seeking…
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults an…
Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that Dr. Christian Behrenbruch, Managing Director and Group CEO…
Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U…
Telix Pharmaceuticals Limited The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. Telix has positively engaged with the FDA on a New Drug Appl…
Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction ideas heading into the autumn. In the U.S., the bank added Vertex Pharmaceuticals…
Telix Pharmaceuticals Limited David Gill appointed Chair of the Telix Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. Dr. Mark Nelson will continue…
Rising treasury and sovereign yields driven by persistent inflation concerns are forcing investors to think harder about where future growth might justify the extra risk. This is where fast-growing stocks with high insider ownership become…
With European bond yields pushing toward multi year highs on persistent inflation concerns, investors are again paying close attention to what they are actually paying for future cash flows. Higher discount rates tend to punish overhyped s…
Global demand tied to AI related investment is shaping trade and capital flows, and that is putting growth companies with clear earnings ambitions back in focus. Investors are searching for businesses that can convert this demand into real…
Telix Pharmaceuticals Limited Q2 2026 Earnings Call Summary - Moby Strategic Execution and Market Leadership Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's…
This article first appeared on GuruFocus. Revenue: $477 million, up 22% year-on-year. EBITDA: $52 million, up 146% year-on-year. Net Profit After Tax: $38 million, up 30% year-on-year. Precision Medicine Revenue: Approximately $390 million…
Key Points Interested in Telix Pharmaceuticals Limited? Here are five stocks we like better. Strong first-half financial performance: Telix reported revenue of $477 million, up 22% year over year, while EBITDA surged 146% to $52 million an…
Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026.…
MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group perform…